SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir ($PLTR) is trending as investors anticipate earnings, with the community debating the stock's valuation amid high P/E ratios and a recent surge to all-time highs. Bulls cite the company's AI prospects and government contracts, while bears express concerns about an overextended valuation and potential post-earnings pullback. Discussions also include speculation about a possible stock split and potential partnerships.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors debate the impact of increased AI spending and its potential to drive future growth, amidst concerns about current profitability. The community is split between those seeing a buying opportunity after the recent dip and others anticipating further declines, with some mentioning a possible partnership with OpenAI. Overall sentiment is mixed, with focus on Meta's AI strategy and comparing it to other tech giants.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as community members discuss the potential for the stock to reach $900 and beyond, driven by optimism around FDA approval of their oral treatment and strong positioning in the weight loss market, while also generating concerns around pricing following Trump's comments. Community members are weighing the potential impact of competition from other pharma companies and strategic moves within the sector.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

ENVB is trending as retail traders discuss its potential for a short squeeze, drawing comparisons to past squeezes like $BYND and $AMC. The community is focused on its low float and recent news, with some anticipating a significant price increase. Some traders are also discussing a reverse split.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

TERN is trending as discussions revolve around its potential in the CML treatment landscape after positive data was presented. Some investors are optimistic about TERN-701's prospects, while others express concerns about the risks associated with Phase 1 stocks and potential dilutions. Amidst the TERN discussion, some traders are also eyeing ENVB for a potential short squeeze similar to BYND.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending downwards, prompting discussions about potential bottom levels and gap fills, as well as tariff implications. Community sentiment is mixed, with some investors expressing frustration while others see it as a buying opportunity. Despite recent earnings, the stock's performance is being weighed against broader market factors and concerns about future growth and consumer trends.

Kimberly-Clark Corp. engages in the manufacture and marketing of products made from natural or synthetic fibers. It operates through the following segments: North America, International Personal Care, and International Family Care and Personal. The North America segment consists of products encompassing each of daily-need categories across consumer and professional channels including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers and other related products. The International Personal Care segment consists of three core categories: Baby & Child Care, Adult Care, and Feminine Care, including disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear and other related products. The International Family Care and Professional segment consists of two core categories: Family Care and Professional, including facial and bathroom tissue, paper towels, napkins, wipers, tissue, towels, soaps and sanitizers and other related products. The company was founded by John A. Kimberly, Havilah Babcock, Charles B. Clark, and Frank C. Shattuck in 1872 and is headquartered in Irving, TX.

Kimberly-Clark Corp.

Kimberly-Clark ($KMB) is trending following news of a $48.7 billion bid to acquire Kenvue ($KVUE), owner of brands like Tylenol and Band-Aid, in a cash-and-stock deal, though some investors express concerns about the debt load and potential dividend impact. The community is discussing merger arbitrage opportunities in $KVUE, potential stock dilution for $KMB, and the CEO's upcoming appearance on CNBC's Mad Money amid share weakness. Others believe that the Tylenol controversy is overblown, and that $KMB is a good long term investment.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

DASH is trending as traders discuss its potential for a ZEC-like surge, with some highlighting its limited supply and comparing its potential to Bitcoin. Community members are actively speculating on price targets and whether DASH will benefit from renewed interest in privacy coins. There's also discussion about DASH's utility and integration with platforms like DoorDash.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is trending amid discussions about its Q3 earnings, which revealed a large cash reserve and no recent buybacks, leading to mixed reactions regarding its valuation and future strategy. The community is debating whether the lack of buybacks signals overvaluation and what Buffett's successor, Greg Abel, might do with the massive cash pile, particularly in the AI and energy sectors. Some investors view BRK.B as a safe haven amidst market volatility, while others express frustration with its recent underperformance compared to high-growth tech stocks.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The DIA is trending due to recent market optimism and anticipation of upcoming economic data releases. Community members are actively discussing potential breakouts and whether the recent rally has legs, especially with key earnings reports on the horizon. Many are also pointing to overbought conditions and warning of a potential pullback, while some are discussing individual components and trading strategies.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Squawk Pod: Big Tech's big challenges & Transportation Sec. Sean Duffy - 11/03/25  Audio Only

Transportation Secretary Sean Duffy addresses the government shutdown's impact on travel and federal travel workers across the country as we enter the second month of the standstill in Washington...

Kimberly-Clark Buying Tylenol Maker Kenvue in $40 Billion Deal

Kimberly-Clark agreed to buy Kenvue in a deal worth roughly $40 billion in a combination that could create a company with $32 billion in revenue and allow it to surpass Unilever to become the...

Halper Sadeh LLC Encourages KVUE, REVG, KMB Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages KVUE, REVG, KMB Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages KVUE, REVG, KMB Shareholders to Contact the Firm to Discuss Their...

Kimberly-Clark to buy Tylenol maker Kenvue in massive consumer merger

Caroline Woods: Big brands and big money - Kimberly-Clark is buying Kenvue in a nearly $50 billion cash and stock deal. That would put Huggies, Kleenex, Band-Aid, Neutrogena and Tylenol all under one...

Shareholder Alert: The Ademi Firm investigates whether Kenvue Inc. is obtaining a Fair Price for its Public Shareholders

Shareholder Alert: The Ademi Firm investigates whether Kenvue Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm investigates whether Kenvue Inc. is...

Kimberly-Clark Corporation (KMB) said on Monday that it has entered into an agreement to purchase Tylenol manufacturer Kenvue (KVUE) in a deal valued at about $48.7 billion.Under the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/kimberly-clark-to-acquire-kenvue-creating-a-32-billion-global-health-and-wellness-leader-302602379.html">deal</a>, Kimberly-Clark will acquire all of the outstanding shares of Kenvue common stock in a cash and stock transaction. Kenvue shareholders will receive $3.50 per share in cash, as well as 0.14625 Kimberly-Clark shares for each Kenvue share held at closing, for a total consideration of $21.01 per share to Kenvue shareholders. This represents a premium of about 46% from KVUE’s closing price on Friday and values Kenvue at an enterprise value of approximately $48.7 billion, Kimberly-Clark said.<h2 class="st-heading-2">Ownership Structure</h2>Upon closing, Kimberly-Clark shareholders are expected to own approximately 54% and current Kenvue shareholders are expected to own approximately 46% of the combined company, it added. Kimberly-Clark CEO Mike Hsu will be the chief executive of the combined company, and three members of the Kenvue Board will join the Kimberly-Clark board at the closing of the transaction.The transaction has been unanimously approved by the Board of Directors of both companies, Kimberley-Clark said. It is expected to close in the second half of 2026.According to Kimberly, Kenvue is uniquely positioned at the intersection of consumer packaged goods and healthcare, and the combination of the two companies can create a combined portfolio of complementary products. While Kimberly-Clark is known for Huggies diapers and Kleenex, Kenvue’s popular products include Band-Aid, Benadryl, Listerine, Neutrogena, and Tylenol.Notably, market expert Jim Cramer said on Monday that he sees the deal creating a “real rival” to Procter &amp; Gamble (PG).<stembedurl>https://x.com/jimcramer/status/1985312437810389345</stembedurl>Kenvue Chair Larry Merlo, meanwhile, said that the board is confident that the combination represents the "best path forward" for shareholders.Kimberly-Clark expects the combined company to generate approximately $32 billion in annual net revenues and approximately $7 billion in adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) based on current projections for 2025.KVUE shares rose 16% at the time of writing, while KMB stock fell 13%. &nbsp;<h2 class="st-heading-2">The Tylenol Issue</h2>The deal comes on the heels of <a href="https://stocktwits.com/news-articles/markets/equity/kenvue-stock-drops-after-texas-attorney-general-sues-company-alleging-deceptive-marketing-of-tylenol/cLGjSYkR3HD">turbulence</a> at Kenvue, including President Trump linking its popular painkiller Tylenol to autism. In late September, the President linked autism to childhood vaccine use and the use of Tylenol by women when pregnant. Though the claims are not backed by scientific evidence, it has created a divide in opinion on the popular drug. Kenvue has maintained that Tylenol is safe and its consumption is unrelated to autism.&nbsp; Kenvue was spun off from JNJ in 2023. In 2024, Kenvue’s net sales were $15.5 billion, of which Tylenol is estimated to account for about $1 billion.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around KVUE stayed within the ‘bullish’ territory while message volume stayed at ‘normal’ levels.KVUE stock is down by 22% this year and by about 28% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tg-therapeutics-stock-soars-after-company-ups-guidance-for-multiple-sclerosis-drug/cL2NEPSR3zl">TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Kenvue logo is seen displayed on a smartphone screen. U.S. health officials will hold a press conference on autism, which is expected to link Kenvue's Tylenol to the disease. (Illustration by Thomas Fuller/Getty Images)

Kenvue Shares Soar 16% After Inking $48.7B Deal With Kimberly-Clark

Upon closing, Kimberly-Clark shareholders are expected to own approximately 54% and current Kenvue shareholders are expected to own approximately 46% of the combined company. 

Equity

Upon closing, Kimberly-Clark shareholders are expected to own approximately 54% and current Kenvue shareholders are expected to own approximately 46% of the combined company. 


Earnings Preview: Kenvue (KVUE) Q3 Earnings Expected to Decline

Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kenvue Declares Quarterly Cash Dividend

Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is payable on November 26, 2025, to...

Beauty product used by millions recalled for possible bacterial danger

Roughly 1,300 cases of the recalled product were distributed across four states.There is a health risk: The bacterium Pluralibacter gergoviae can cause infections in vulnerable people. However, the...

Texas Sues Tylenol Maker Over Allegedly Omitting Evidence Of Autism Link From Marketing

Texas Sues Tylenol Maker Over Allegedly Omitting Evidence Of Autism Link From Marketing Authored by Zachary Stieber via The Epoch Times (emphasis ours), Tylenol's current and former manufacturer...

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

KVUE
Kenvue Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest KVUE News

KVUEKenvue Inc